公开(公告)号：WO2022266357A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033845

申请日：2022-06-16

申请人： FUSION PHARMACEUTICALS INC. ,  KLINZ, Stephan

发明人： IMBS, Diane-Charlotte ,  LEWKOWICZ, Elodie ,  ROLLAND, Sylvie ,  ROHBAN, Thomas ,  FORBES, John R.

IPC分类号： A61K31/33 ,  C07D403/00 ,  C07D231/14 ,  A61K31/41 ,  A61K31/00

摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：WO2022266354A1

公开(公告)日：2022-12-22

申请号：PCT/US2022/033841

申请日：2022-06-16

申请人： FUSION PHARMACEUTICALS INC. ,  KLINZ, Stephan

发明人： IMBS, Diane-Charlotte ,  LEWKOWICZ, Elodie ,  ROLLAND, Sylvie ,  ROHBAN, Thomas ,  FORBES, John R.

IPC分类号： A61K47/00 ,  A61K31/165 ,  A61K31/33 ,  A61K31/00

摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound and NAPOLI for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：WO2022226299A1

公开(公告)日：2022-10-27

申请号：PCT/US2022/025933

申请日：2022-04-22

申请人： FUSION PHARMACEUTICALS INC.

发明人： BURAK, Eric S. ,  FORBES, John R. ,  SIMMS, Ryan W.

IPC分类号： A61K51/04 ,  A61K51/08 ,  C07B59/00

摘要： The present disclosure relates to methods of treating a subject having cancer with an 225Ac-radiopharmaceutical, which comprises 225Ac chelated with a compound of Formula (I) wherein the compound binds to neurotensin receptor 1 (NTSR1) and does not cross the blood-brain barrier, and wherein the 225Ac-radiopharmaceutical is administered at a dosage of less than 10 MBq/kg of body weight of the subject or is administered as a unitary dosage of less than 40 MBq to the subject.

公开(公告)号：WO2022261770A1

公开(公告)日：2022-12-22

申请号：PCT/CA2022/050961

申请日：2022-06-16

申请人： FUSION PHARMACEUTICALS INC.

发明人： IMBS, Diane-Charlotte ,  LEWKOWICZ, Elodie ,  MCEWAN, Alexander ,  ROHBAN, Thomas ,  ROLLAND, Sylvie ,  STEVENS, Daniel ,  FORBES, John R.

IPC分类号： A61K31/4155 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/4745 ,  A61K51/04 ,  A61P35/00 ,  C07D239/553 ,  C07D403/12 ,  C07D475/04 ,  C07D491/22 ,  C07F15/00

摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：WO2022261771A8

公开(公告)日：2022-12-22

申请号：PCT/CA2022/050962

申请日：2022-06-16

申请人： FUSION PHARMACEUTICALS INC.

发明人： IMBS, Diane-Charlotte ,  LEWKOWICZ, Elodie ,  MCEWAN, Alexander ,  ROHBAN, Thomas ,  ROLLAND, Sylvie ,  STEVENS, Daniel ,  FORBES, John R.

IPC分类号： A61K51/04 ,  A61K31/337 ,  A61K31/7068 ,  A61K47/64 ,  A61K51/00 ,  A61P35/00

摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：WO2022261771A1

公开(公告)日：2022-12-22

申请号：PCT/CA2022/050962

申请日：2022-06-16

申请人： FUSION PHARMACEUTICALS INC.

发明人： IMBS, Diane-charlotte ,  LEWKOWICZ, Elodie ,  MCEWAN, Alexander ,  ROHBAN, Thomas ,  ROLLAND, Sylvie ,  STEVENS, Daniel ,  FORBES, John R.

IPC分类号： A61K51/04 ,  A61K31/337 ,  A61K31/7068 ,  A61K47/64 ,  A61K51/00 ,  A61P35/00

摘要： The present invention relates to a combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.

公开(公告)号：WO2021207086A1

公开(公告)日：2021-10-14

申请号：PCT/US2021/025800

申请日：2021-04-05

申请人： FUSION PHARMACEUTICALS INC. ,  BURAK, Eric S.

发明人： FORBES, John R. ,  SIMMS, Ryan W.

IPC分类号： A61K33/24 ,  A61K33/241 ,  A61K33/245 ,  A61K33/30

摘要： Radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and a TEM-1 targeting moiety. Pharmaceutical compositions of such radioimmunoconjugates and methods of treatment for conditions, e.g., cancer, using such pharmaceutical compositions.